Fredericton farmers' market receives nearly $1 million
A farmers' market in Fredericton will be able to do several upgrades after receiving nearly $1 million in government money.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
25 minutes ago
- National Post
AXL teams with RSM Canada to build AI solutions for Canada's future
Article content TORONTO — AXL, a Canadian venture studio transforming world-class applied AI research into high-growth companies, and RSM Canada LLP ('RSM'), a leading global provider of assurance, tax and consulting services, have entered into a strategic collaboration. Together, the two organizations are driving innovation by challenging existing models and reimagining what's possible in professional services by integrating AI advancements with real-world business needs. Article content As part of the collaboration, RSM will serve as the exclusive provider of accounting, tax and consulting services to AXL, offering strategic guidance, compliance expertise, and growth planning support. Additionally, RSM will act as a preferred provider of these services to AXL's portfolio of startup companies. Article content RSM is also one of several leading Canadian organizations participating in AXL's AI Catalyst program, a corporate partnership initiative designed to validate and accelerate breakthrough ideas driven by real industry demand. The goal is to fast-track the commercialization of high-potential AI applications and ensure Canadian innovations are built into the country's economic future, rather than being exported before they scale. Article content 'Canada doesn't have an innovation gap, it has a commercialization gap,' says Dr. Daniel Wigdor, co-founder and CEO of AXL. 'With RSM, we're taking demand signals from the market and moving fast to turn that into scalable, enterprise-ready solutions. This is execution over hype. This is how Canada leads—not just in ideas, but in outcomes.' Article content Canada leads in AI academic research but struggles to retain its economic benefits, as much of its advancements are commercialized internationally. Article content Fewer than 20 per cent of mid-sized Canadian companies have begun adopting AI, according to the OECD, citing barriers such as limited technical talent, high costs and an uncertain return on investment. These findings are echoed in RSM's 2025 Middle Market AI Survey, which highlights similar challenges and underscores the need for practical, scalable AI solutions tailored to the middle market. Article content Meanwhile, nearly 75 per cent of AI patents from Canada's top institutes are acquired by international tech firms, with only 7 per cent remaining in the country. The United Nations also estimates that fewer than half of Canada's top AI innovations are ever patented, highlighting a critical disconnect between invention and impact. Article content By integrating real-time industry feedback, the AXL-RSM collaboration advances Canadian AI venture growth, commercialization and talent development, ensuring solutions scale domestically and drive lasting economic impact. Article content 'We're seeing incredible momentum around AI and the value it can unlock,' said Harry Blum, national managing partner at RSM Canada. 'With AXL as a strategic collaborator, we're accelerating innovation—helping businesses move beyond legacy models and positioning them to grow, compete and thrive in a future-ready economy, while embedding AI across our own solution sets.' Article content The relationship represents a direct commitment to Canada's AI ecosystem, powering homegrown innovation while reinforcing a shared commitment to helping Canadian businesses lead in the digital economy. RSM recently committed US$1 billion globally to AI, with a focus on helping middle market businesses adopt AI, especially those ready to innovate but lacking scale or resources. This initiative by RSM further aligns with AXL's vision of positioning Canada as a global leader in applied AI by bridging the gap between research and commercialization. Article content Together, AXL and RSM aim to unlock the next wave of AI-driven economic growth, bringing AI solutions that empower Canadian businesses and proving the benefit of AI not just in theory but in practice. Article content To learn more about how AXL is fuelling Canada's AI research-to-commercialization pipeline, visit their website at Article content About AXL Article content AXL is a Canadian venture studio transforming world-class research into high-growth companies that shape the future of applied AI. Led by seasoned tech entrepreneurs and applied AI experts, AXL's mission is to ensure Canada's top breakthroughs are built and scaled at home. By connecting academia with real market demand and full-stack venture creation, AXL helps Canada move from invention to impact, anchoring talent, intellectual property, and long-term economic value within the country. For more information, visit and connect with us on Article content About RSM Canada Article content RSM empowers middle market companies worldwide to take charge of change. The clients we serve are the engine of global commerce and economic growth. Our unique middle market perspective makes RSM the natural choice for growth-oriented, internationally active organizations seeking relevant insights and tailored, innovative solutions for a complex and changing world. With a global reach spanning more than 120 countries, we instill confidence in a world of change by bringing the full power of RSM to make a lasting impact on our clients, colleagues and communities. Article content RSM Canada LLP provides public accounting services and is the Canadian member firm of RSM International, a global network of independent assurance, tax and consulting firms. RSM Canada Consulting LP provides consulting services and is an affiliate of RSM US LLP, a member firm of RSM International. For more information visit like us on Facebook, follow us on X and/or connect with us on LinkedIn. Article content Article content Article content Article content Contacts Article content For media inquiries: Article content Article content Article content Article content
National Post
25 minutes ago
- National Post
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
Article content SAN ANTONIO — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. Article content 'As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives,' said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. Article content 'We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science,' Ms. Zannes said. 'Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics.' Article content The Canadian patent (Patent No. 3,136,245) – titled 'System and Method for Determining Lung Health' – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. Article content CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Article content About CyPath® Lung Article content CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit Article content About bioAffinity Technologies, Inc. Article content bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Article content Forward-Looking Statements Article content Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Article content Article content Article content Article content Article content Contacts Article content bioAffinity Technologies Article content Article content Julie Anne Overton Article content Article content Director of Communications Article content Article content
National Post
25 minutes ago
- National Post
Corpay Cross-Border Named the Official FX Partner of the FIM World Supercross Championship
Article content Article content TORONTO — Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay's Cross-Border business has entered into an agreement with the FIM World Supercross Championship, the premier championship for international stadium supercross racing, to become their Official Foreign Exchange (FX) Partner. Article content Through this partnership, World Supercross will be able to utilise Corpay Cross Border's innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. Additionally, Corpay Cross-Border's award-winning platform will enable them to manage their global payments from a single point of access. Article content 'The FIM World Supercross Championship is truly a global series focused on bringing the world's best supercross riders to cities and stadiums across the globe, and we are honoured to be named their Official FX Partner,' said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. 'I am confident that World Supercross will benefit from access to our comprehensive FX risk management and cross-border payments solutions, along with our experience gained within the world of sports.' Article content 'Having worked with Corpay for many years previously, I was very happy to bring them on board to the World Supercross family,' said Mike Papadimitriou, Chief Financial Officer at Bia Sports Group. 'Corpay brings a level of trust, technology, and efficiency to cross-border payments that aligns perfectly with the ambitions for our global Championship.' Article content Uniquely, this Partnership will form part of a broader engagement between Corpay and Bia Sports Group, whereby the parties will seek mutual opportunities and efficiencies across the expanding portfolio of Bia Sports Group companies. Article content About Corpay Article content Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Corpay's suite of modern payment solutions help its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings) and payables (e.g. paying vendors). This results in our customers saving time and ultimately spending less. Corpay Cross-Border refers to a group of legal entities owned and operated by Corpay, Inc. Article content Article content Article content Contacts Article content Corpay Contact: Article content Article content Brad Loder Article content Article content Article content Article content
